» Articles » PMID: 10493521

Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa)

Overview
Journal Cancer Res
Specialty Oncology
Date 1999 Sep 24
PMID 10493521
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Almost 70% of urinary bladder neoplasms present as low-grade papillary noninvasive tumors (stage pTa). To determine which genomic alterations can occur in pTa tumors of different grades and to evaluate the prognostic significance of chromosomal imbalances, we analyzed 113 pTa tumors (40 grade 1, 55 grade 2, 18 grade 3) by comparative genomic hybridization. pTaG1 (1.9 +/- 2.0) and pTaG2 (3.1 +/- 2.9) tumors had only few genomic alterations with 9q- (44%), 9p- (36%), and -Y (21%) being most prevalent. Neither the total number of aberrations nor any individual alteration was linked to the risk of recurrence in 95 pTaG1/G2 tumors with clinical follow-up information. pTaG3 tumors were characterized by a high number of alterations (7.7 +/- 4.5; P < 0.0001 for G3 versus G2). Several chromosomal imbalances that have previously been reported to be typical for invasive bladder neoplasms were significantly more frequent in pTaG3 than in pTaG2 tumors, including 2q-, 5p+, 5q-, 6q-, 8p-, 10q-, 18q-, and 20q+. A malfunction of genes at these loci may contribute to the development of high-grade urothelial neoplasias. However, there is no evidence for a direct role of these alterations for development of invasive tumor growth.

Citing Articles

CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course.

Plage H, Furlano K, Neymeyer J, Weinberger S, Gerdes B, Hubatsch M BJUI Compass. 2024; 5(6):585-592.

PMID: 38873357 PMC: 11168773. DOI: 10.1002/bco2.354.


Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas.

Muller J, Plage H, Elezkurtaj S, Mandelkow T, Huang Z, Lurati M Front Oncol. 2024; 13:1342367.

PMID: 38282671 PMC: 10811247. DOI: 10.3389/fonc.2023.1342367.


Diagnostic performance of an immunoassay based on urine exfoliated cell enrichment nanotechnology for upper tract urothelial carcinoma: a retrospective, monocentric study.

Wang X, Zhang S, Wu L, Feng B, Shen H, Gu Y BMC Urol. 2022; 22(1):194.

PMID: 36434570 PMC: 9700989. DOI: 10.1186/s12894-022-01122-4.


FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.

Zhou H, He F, Mendelsohn C, Tang M, Huang C, Wu X Sci Rep. 2016; 6:25596.

PMID: 27157475 PMC: 4860634. DOI: 10.1038/srep25596.


CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.

Wang Y, Wu W, Wang W, Huang H, Li W, Yeh B Oncotarget. 2015; 6(31):31069-84.

PMID: 26307680 PMC: 4741589. DOI: 10.18632/oncotarget.5209.